
The PharmTech team focused on its coverage of AAPS PharmSci 360 this week, conducting interviews with experts on a range of topics including formulation platforms, AI, amorphous solid dispersions, and animal studies.
A small-volume parenteral formulation of NB1011, an enzyme-catalyzed therapeutic activation compound, was successfully developed for intravenous administration.
over 23 years ago
June 2003over 23 years ago
From Genome Exploration to Drug Developmentover 23 years ago
Are you ready for Gen3over 23 years ago
Outsourcing Outlook





